Boehringer Ingelheim: CHMP recommends conditional marketing authorization for Spesolimab as first in class treatment option for generalized pustular psoriasis flares

CHMP positive opinion is based on evidence from the EFFISAYIL 1 trial, the largest clinical trial in patients with generalized pustular psoriasis (GPP) flares1 GPP is a rare and potentially

Related Keywords

Japan ,Paris ,France General ,France ,Petra Kienle ,Carinne Brouillon ,Global Consensus Delphi Panel ,Corporate Communications ,Boehringer Ingelheim ,European Medicine Agency ,Medicinal Products ,Human Use ,Saint Louis University Hospital ,Managing Directors ,Human Pharma ,Boehringer ,Ingelheim ,Thmp ,Ecommends ,Onditional ,Marketing ,Authorization ,Spesolimab ,First ,Glass ,Treatment ,Option ,Generalized ,Pustular ,Psoriasis ,Uglares ,